Rheumatology is the discipline of internal medicine that involves the
diagnosis and treatment of rheumatic diseases. Rheumatic diseases are
characterized by the inflammation that affects joints, tendons,
ligaments, bones and sometimes organs. Rheumatic diseases are also
called as musculoskeletal disease causes severe pain, deformity and
morbidity and leads to heavy economic burden due to high cost of
treatment. There are more than 100 different types of rheumatic
diseases with different symptoms and the symptoms of these diseases
to all age groups. The global prevalence of rheumatic diseases varies
between 0.3-1% worldwide and is women are more likely to develop the
symptoms of these diseases than men. the most common types of
rheumatic disease includes the rheumatoid arthritis (RA),
osteoarthritis (OA), gout , psoriatic arthritis, ankylosing
spondylitis.
Out of the rheumatoid arthritis disease has high prevalence rates
than other disease and accounts for the major share in global
rheumatology therapeutics market. There are many different drugs and
medications have been developed including biologics and biosimilars.
Disease modifying anti-rheumatic drugs (DMARDs), nonsteroidal
anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs
are some of the most commonly used drugs for the treatment of
different types of rheumatic diseases. The NSAIDs are widely and
frequently used for the symptomatic treatment of rheumatoid arthritis
and osteoarthritis. Most of the regulatory authorities recommends the
use of DMARDs as the first line of treatment for rheumatoid arthritis
after diagnosis of this disease.
The global rheumatology therapeutics market is projected to be driven
by the increasing geriatric population in developed countries,
increase in the number of new drugs approval and growing R&D
investments. According to CDC, more than 54 million American are
affected with arthritis in 2017 and it projected that by the end of
2025, this number would reach to 78 million. Also according to world
arthritis day, more than 120 million people in European Union are
affected by some of the forms of arthritis. The growing geriatric
population in developed countries is likely to be key driving factor
for global rheumatology therapeutics market.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494
The demand for the development of newer and technologically enhanced
products such as biologics and biosimilars (generic of biologics) is
growing globally. Hence, major players operating in the rheumatology
therapeutics market are investing in research and development
programs to develop new drugs. In 2015, Takeda Pharmaceuticals
invested US$ 3.2 Bn in research and development activities. According
to an annual report published by GlaxoSmithKline plc. In 2015, the
company partnered with more than 1,500 companies and other academic
organizations around the world for development of new drugs.
Global rheumatology therapeutics market is broadly segmented into
five segment based on drug class, disease indication, by route of
administration, by distribution channel and by geography. By drug
class, the market is segmented into disease modifying anti-rheumatic
drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs),
corticosteroids, uric acid drugs and others. DMARDs segment dominated
the global rheumatology therapeutics market in 2016 owing to increase
in usage of these drugs in early stage of disease and growing
adoption of biologics drugs for treatment of moderate to severe
rheumatoid arthritis and osteoarthritis.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1494
The DMARDs are further sub-segmented into synthetic disease-modifying
anti-rheumatic drugs and biologic disease-modifying anti-rheumatic
drugs. Corticosteroids segment is projected to witness the highest
growth rate during forecast period. By disease indication, market is
segmented into rheumatoid arthritis (RA), osteoarthritis (OA), gout,
ankylosing spondylitis, psoriatic arthritis and others. By route of
administration market is segmented into oral route, parenteral route
and topical. The distribution channel for rheumatology therapeutics
market includes the hospital pharmacy, retail pharmacy and online
pharmacy.
By Geography, the global rheumatology therapeutics market is
segmented into North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. These regions have been further
segmented by countries, methods, applications and end-users. North
America dominated the market and is anticipated to lose its market
share to Asia Pacific region by the end of 2025.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1494
The competition matrix section included in the report is likely to
assist the existing players to increase their market shares and new
companies to establish their presence in the global rheumatology
therapeutics market. The report also profiles major players in the
market based on various attributes such as company overview,
financial overview, SWOT analysis, key business strategies, product
portfolio, and recent developments. Major players operating in the
rheumatology therapeutics market include Amgen, Inc., AbbVie, Inc.,
Pfizer, Inc. , Janssen Biotech, Inc. (Johnson & Johnson),
Novartis AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.),
Bristol-Myers Squibb Company, Merck & Co., Inc. , Sanofi, and
Takeda Pharmaceutical, among others.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment